IMMUNE CELL ENGINEERING MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2023 - 2030)

Immune Cell Engineering Market Size and Trends

The global immune cell engineering market size is expected to reach US$ 11.66 Bn by 2030, from US$ 2.82 Bn in 2023, at a CAGR of 22.5% during the forecast period.

Immune cell engineering involves modifying immune cells such as T cells, NK cells, and dendritic cells for research and therapeutic applications. Key applications include the development of immunotherapies like CAR T-cell therapy, studying immune responses, and drug discovery. The growth of this market is driven by rising investments in cell-based research and advancements in gene-editing technologies.

Global Immune Cell Engineering Market Drivers:

• Rising Incidence of Chronic Diseases: The rising prevalence of chronic diseases like cancer, autoimmune disorders, and cardiovascular diseases around the world is a key factor driving the growth of the immune cell engineering market. Diseases like cancer severely affect the immune system, and cell-based immunotherapies are being increasingly adopted as an effective therapeutic strategy. For instance, engineered T cell therapies like CAR T-cell therapy have shown promising results in certain hematological cancers. The success of such advanced immunotherapies is driving investments in immune cell engineering research to develop treatments for various chronic diseases.
• Technological Advancements in Cell Engineering: Continuous advances in gene editing, cell isolation, and expansion technologies are significantly supporting the growth of the immune cell engineering industry. The development of efficient gene editing tools like CRISPR/Cas9 has enabled precise and safer modifications in immune cells. Other technologies, like microfluidics and high-throughput assays, are enhancing cell engineering workflows. Growing understanding of immune cell signaling pathways and interactions is also enabling the engineering of enhanced immune cell therapies. These ongoing technological innovations are expected to expand the scope and applications of engineered immune cells.
• Growth in Cell Therapy Clinical Trials: There has been a remarkable surge in the number of clinical trials evaluating novel engineered immune cell therapies over the last decade. Several companies and academic institutions are increasingly investigating the safety and efficacy of various modified immune cell therapies. For instance, the number of CAR T-cell therapy trials rose from just 1 in 2009 to over 300 in 2018. The encouraging response rates from some of these trials are driving increased activity in this space. The exponential growth of global cell therapy clinical trials signifies the rising adoption of immune cell engineering.
• Increasing Investments in Cell-based Research: Public and private entities are steadily ramping up their investments in cell engineering research and infrastructure development to support advancements in the field. Government bodies like the NIH and charities like the Cancer Research Institute have expanded funding for academic research on engineered immune cells and immunotherapy. Leading biopharma players have also enhanced capital allocation for internal immunotherapy programs and related strategic acquisitions. These rising investments in research and development (R&D) and infrastructure to aid continued innovation in engineered immune cells are fueling market growth.

Global Immune Cell Engineering Market Trends:

• Shift Towards Point-of-Care Manufacturing: Decentralized point-of-care manufacturing models for engineered cell therapies are evolving to make treatments faster and more personalized. Onsite hospital biofactories with automated manufacturing capability can customize cell therapies using a patient’s cells and deliver it rapidly. Several companies are developing turnkey point-of-care cell engineering platforms that require minimal expertise. Enabling wider accessibility through decentralized manufacturing close to the patient is an important trend.
• Rising Industry-Academia Collaborations: Robust partnerships between industry and academic institutes are on the rise to combine capabilities and fuel innovation in immune cell engineering. Pharmaceutical players are collaborating with universities with proprietary technologies or research expertise to develop next-gen immunotherapies. Such open innovation networks allow leveraging of synergistic capabilities. Increasing licensing deals and strategic partnerships among biopharma firms, technology providers, and academic groups will remain a key trend.
• Growing Focus on Off-The-Shelf Therapies: There is a rising focus on developing universal off-the-shelf engineered T cell products that can circumvent the costs and delays of personalization. Companies are working on proprietary techniques to generate allogeneic therapies using healthy donor cells that will not face rejection issues. Advances in cell banking, genetic modifications, and use of memory T cell subsets are aiding such efforts. The progress towards off-the-shelf engineered cell therapies is expected to expand treatment access.
• Emergence of Synthetic Biology Approaches: The field of engineered immune cells is increasingly incorporating principles of synthetic biology to create smarter, multifunctional therapeutic cells. Gene circuits, logic gating, and modular receptor scaffolds are being leveraged to design complex cell behaviors and sensing capabilities. Companies like Poseida Therapeutics and T-CURX are building extensive capabilities in synthetic biology and next-gen cell reprogramming. The application of such innovative platforms will enable more advanced and nuanced immune cell therapies.